Amneal Pharmaceuticals makes effective opioid settlement with states and subdivisions

Amneal Pharmaceuticals, Inc.

Amneal determined to make effective its Nationwide Opioids Settlement Agreement on Jan 29, 2026, with sufficient state and subdivision participation.
Company will pay $88.5 million to participating states and subdivisions.
Company will provide up to $177.4 million in naloxone nasal spray (valued at $125 per twin pack) to treat opioid overdoses.
Settling parties can opt for cash up to $44.4 million (25% of product value) during last four years of ten-year term, potentially raising total cash to $132.9 million.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.